CN1720054A - 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途 - Google Patents

阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途 Download PDF

Info

Publication number
CN1720054A
CN1720054A CNA038114879A CN03811487A CN1720054A CN 1720054 A CN1720054 A CN 1720054A CN A038114879 A CNA038114879 A CN A038114879A CN 03811487 A CN03811487 A CN 03811487A CN 1720054 A CN1720054 A CN 1720054A
Authority
CN
China
Prior art keywords
glucosides
derivant
apomorphine
glycoside
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038114879A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·霍利克
H·拉马纳坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAIN N BEYOND BIOTECH
Original Assignee
BRAIN N BEYOND BIOTECH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRAIN N BEYOND BIOTECH filed Critical BRAIN N BEYOND BIOTECH
Publication of CN1720054A publication Critical patent/CN1720054A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNA038114879A 2002-03-19 2003-03-19 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途 Pending CN1720054A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36545402P 2002-03-19 2002-03-19
US60/365,454 2002-03-19

Publications (1)

Publication Number Publication Date
CN1720054A true CN1720054A (zh) 2006-01-11

Family

ID=28454658

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038114879A Pending CN1720054A (zh) 2002-03-19 2003-03-19 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途

Country Status (9)

Country Link
US (1) US20060004190A1 (https=)
EP (1) EP1496915A1 (https=)
JP (1) JP2005526790A (https=)
KR (1) KR20050008658A (https=)
CN (1) CN1720054A (https=)
AU (1) AU2003223304A1 (https=)
BR (1) BR0308567A (https=)
CA (1) CA2479372A1 (https=)
WO (1) WO2003080074A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307876B (zh) * 2008-12-10 2014-12-10 赛诺菲 吗啡-6-葡萄糖苷酸或其一种衍生物的合成
CN107548388A (zh) * 2014-12-23 2018-01-05 纽罗德姆有限公司 阿朴吗啡的晶体形态及其用途
CN113784965A (zh) * 2019-05-20 2021-12-10 H.隆德贝克有限公司 (2s,3s,4s,5r,6s)-3,4,5-三羟基-6-(((4ar,10ar)-7-羟基-1-丙基-1,2,3,4,4a,5,10,10a-八氢苯并[g]喹啉-6-基)氧基)四氢-2h-吡喃-2-甲酸的新固体形式
CN114773409A (zh) * 2022-04-27 2022-07-22 江西艾立斯特生物科技有限公司 一种2,3,4,6-四-o-乙酰基-吡喃葡萄糖的制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
PL2854764T3 (pl) 2012-06-05 2019-07-31 Neuroderm Ltd Kompozycje zawierające apomorfinę i kwasy organiczne oraz ich zastosowania
CA2930410A1 (en) 2013-11-11 2015-05-14 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
JP7320507B2 (ja) 2017-11-24 2023-08-03 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
US20250361252A1 (en) 2022-06-15 2025-11-27 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785014A (en) * 1985-06-07 1988-11-15 Yale University Use of clonidine in memory enhancement
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
JP3310982B2 (ja) * 1994-04-22 2002-08-05 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 男性の勃起機能不全を改善するための剤形及び方法
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6001845A (en) * 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO1999065563A1 (en) * 1998-06-19 1999-12-23 Genetronics, Inc. Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
BR0109515A (pt) * 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307876B (zh) * 2008-12-10 2014-12-10 赛诺菲 吗啡-6-葡萄糖苷酸或其一种衍生物的合成
CN107548388A (zh) * 2014-12-23 2018-01-05 纽罗德姆有限公司 阿朴吗啡的晶体形态及其用途
CN113784965A (zh) * 2019-05-20 2021-12-10 H.隆德贝克有限公司 (2s,3s,4s,5r,6s)-3,4,5-三羟基-6-(((4ar,10ar)-7-羟基-1-丙基-1,2,3,4,4a,5,10,10a-八氢苯并[g]喹啉-6-基)氧基)四氢-2h-吡喃-2-甲酸的新固体形式
CN113784965B (zh) * 2019-05-20 2024-05-03 H.隆德贝克有限公司 一种化合物的新固体形式
CN114773409A (zh) * 2022-04-27 2022-07-22 江西艾立斯特生物科技有限公司 一种2,3,4,6-四-o-乙酰基-吡喃葡萄糖的制备方法
CN114773409B (zh) * 2022-04-27 2023-12-15 江西艾立斯特生物科技有限公司 一种2,3,4,6-四-o-乙酰基-吡喃葡萄糖的制备方法

Also Published As

Publication number Publication date
US20060004190A1 (en) 2006-01-05
WO2003080074A1 (en) 2003-10-02
AU2003223304A1 (en) 2003-10-08
KR20050008658A (ko) 2005-01-21
EP1496915A1 (en) 2005-01-19
CA2479372A1 (en) 2003-10-02
JP2005526790A (ja) 2005-09-08
BR0308567A (pt) 2007-01-09

Similar Documents

Publication Publication Date Title
CN1720054A (zh) 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途
CN1438891A (zh) 具有甲脒修饰的单环碱基的核苷类似物
CN1483039A (zh) 作为降血胆甾醇剂的糖取代的2-氮杂环丁烷酮
JP2014139257A (ja) 高い経口バイオアベイラビリティを有するモルフィナン誘導体
CN103781472A (zh) 丙泊酚苷衍生物的合成和使用
CA2484891A1 (en) Conjugates comprising central nervous system active drug
CN1031878C (zh) 蒽环苷的制备方法
CN1027264C (zh) 粟籽豆精胺苷的制备方法
US7217696B2 (en) Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
HK1084020A (en) Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
JPH10513485A (ja) オピエート性物質の糖結合体
CN1224626C (zh) β－D－5－硫代木糖衍生物、其制备方法及医疗用途
US6548485B2 (en) Stable antitumor drug
CN113490498A (zh) 包含16α-溴-3β-羟基-5α-雄甾烷-17-酮及其水合物、衍生物和类似物的水性悬浮液组合物、制剂和水中可分散的干燥的组合物
US9315539B2 (en) 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer
EP0873347A2 (fr) Nouveaux derives amines de 2", 3" didesoxyglycosides d'epipodophyllotoxine, leur procede de preparation, leur utilisation comme medicament et leur utilisation destinee aux traitements anticancereux
CN1063486A (zh) 脱乙酰基秋水仙素衍生物
JP2005511550A (ja) エトポシドおよび類似体の誘導体、ならびにそれを含有する医薬組成物
WO2001027129A1 (en) Glycosides and orthoester glycosides of raloxifene and analogues and the use thereof
JP5616355B2 (ja) モルフィン−６−グルクロニドの２環式誘導体、この調製方法および治療法でのこの使用
US8680300B2 (en) Dioxanes derived from regrouping carbohydrates and C-glycosides, process for obtaining same and uses thereof
Sawada et al. Synthesis of γ-Lactone-Type Sialic Acid, an Isomer of 2, 3-Dehydrosialic Acid
HK40060651A (en) Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof
HK1238495A1 (en) Morphinan derivatives with high oral bioavailability
EP2951189A1 (fr) Macrolides utiles comme agents anticancereux

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084020

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1084020

Country of ref document: HK